FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1070-1071 September 4, 2008 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Thomas, J. PubMed Citation

To the Editor: In their article on methylnaltrexone for opioid-induced constipation in patients with advanced illness, Thomas et al. (May 29 issue)¹ point out that the effectiveness of methylnaltrexone appeared to be undiminished throughout the 2-week, double-blind trial, as well as during the 3-month, open-label extension phase. However, during the trial, the percentage of positive responses to the drug decreased from 48% after the first dose to 38% after the dose received on day 13. Although this decrease was not significant (P=0.13 by the chi-square test for trend), it becomes more relevant if we recognize that there may have been . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.